Congratulations to the Structure Therapeutics team for announcing positive topline data from its ACCESS clinical program for aleniglipron, an oral GLP-1 receptor agonist.
Julio Rosenstock, MD, Chair of the ACCESS program Steering Committee and Senior Scientific Advisor at Velocity, is quoted in the press release: “The weight-lowering data from these ACCESS studies, without any evidence of a plateau by Week 36, are very encouraging — particularly weight loss of up to 15.3% in ACCESS II that hopefully will be confirmed in larger, longer-term studies… As once-daily oral, non-peptide, small molecule GLP-1 RAs such as aleniglipron become available, they have the potential to transform obesity treatment and broaden access, which could have a profound impact on patients globally.”
Key findings:
- Phase 2b ACCESS study: 120 mg dose → 11.3% mean weight loss (~27 lbs) at 36 weeks
- Exploratory ACCESS II study: 240 mg dose → up to 15.3% mean weight loss (~35 lbs) at 36 weeks
Read the full press release: https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access
